A former insulin pump executive has noted that Tandem (NASDAQ: TNDM), who reported results yesterday, is like the cat that has nine lives only they used up all nine but have been granted one more. In fact, no one in the insulin pump arena, nor us here at Diabetic Investor can believe that the company has survived this long. Tandem has always had an excellent product that was not the problem, no the problem has always been running a commercially viable insulin pump company. Looking at the results and listening to the call we came thinking; ok they ain’t . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.